Isothiochroman

A 1-bromomethylbenzoxepin prepared as in Preparation 1 is stirred in ethylene glycol with 1.0 to 2.0 equivalents of HNR.sub.9 R.sub.10. An excess of triethylamine is added. After the reaction is complete, the mixture is partitioned between aqueous K.sub.2 CO.sub.3 or Na.sub.2 CO.sub.3 and CH.sub.2 Cl.sub.2. The organic phase is dried over Na.sub.2 SO.sub.4 and concentrated. The residue is chromatographed on silica gel. The product is either crystallized or converted to its salt. The salt is formed by treating a solution of the compound with an appropriate acid in a suitable solvent.

A mixture of 3.50 g (0.0116 moles) of 1-bromomethyl-7,8-dimethoxy-2-benzoxepin, 2.51 g (0.0139 moles) of p-fluorophenyl piperazine, 1.94 ml (0.0139 moles) of triethyl amine, and 125 ml of ethylene glycol is heated under N.sub.2 at 100.degree. for 8 hours. After cooling, the reaction mixture is extracted with CH.sub.2 Cl.sub.2, aq. NaHCO.sub.3, and H.sub.2 O. The organic layer is filtered through Na.sub.2 SO.sub.4 and taken to dryness. The crude reaction mixture is then chromatographed on silica gel using 50% Skellysolve.RTM. B as eluant to give 0.60 g (13%) of product is then crystallized from methylenechloride/Skellysolve.RTM. B to yield 1-(4-fluorophenyl)-4-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl) methyl]-piperazine, m.p. 135.degree.-136.degree. C.

Analysis Calcd. for: C.sub.23 H.sub.29 FN.sub.2 O.sub.3 C, 68.97; H, 7.30; N, 7.00. Found: C, 68.68; H, 7.12; N, 6.82.

The following 1-methyl substituted-1,3,4,5-tetrahydro-2-benzoxepines are prepared according to the procedure of Example 1, in some cases with minor variations therefrom. The nmr spectra are consistent with the assigned structures.

A mixture of 2.00 g (7.39 mmol) of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl)]ethyl chloride and 2.8 g (14.5 mmol) of 1-(3-chlorophenyl)piperazine is stirred at 85.degree. to 36 hours in 1 ml of ethylene glycol and 10 ml of toluene. Excess toluene is added and the solids are removed by filtration from the warm solution. The organic phase is concentrated. The product was recrystallized from Cl.sub.2 and toluene to give 1.09 g of product, m.p. 125.degree.-126.degree..

Analysis Calcd. for: C.sub.24 H.sub.31 ClN.sub.2 O.sub.3 C, 66.88; H, 7.25; N, 6.50 Found: C, 66.68; H, 7.49; N, 6.31.

The following 1-ethyl substituted -1,3,4,5-tetrahydro-2-benzoxepins are prepared according to the procedure of Example 10a, in some cases with minor variations therefrom. The nmr spectra are consistent with the assigned structures.

Following the procedure used in Examples 1 through 10, but substituting the appropriate 1 haloalkylbenzoxepin, the following compounds of formula 1 can be made (Table 8). ##STR40## R.sub.1 ' R.sub.1 " R.sub.1 "' R.sub.1 "" R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6 R.sub.7 R.sub.8 n NR.sub.9 R.sub.10 H H propyl OCH.sub.3 H H H H H H H 1 ##STR41## H H H OCH.sub.3 H H H H H H H 1 ##STR42## OCH.sub.3 OCH.sub.3 H H H H H H H H H 1 ##STR43## H OH H H H Br H H H H H 4 ##STR44## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 5 ##STR45## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H H 5 ##STR46## H OCH.sub.3 OCH.sub.3 H H H ##STR47## H H H 5 ##STR48## H OC.sub.3 H.sub.7 OC.sub.3 H.sub.7 H * H * H H H H 5 ##STR49## H H OCH.sub.3 OCH.sub.3 H H ##STR50## H H H H 2 ##STR51## H OH OH H C.sub.3 H.sub.7 H H H H H H 2 ##STR52## H OCH.sub.3 OCH.sub.3 CF.sub.3 H H H H H H H 1 ##STR53## H OCH.sub.3 OCH.sub.3 H H H H H H H H 2 ##STR54## H OCH.sub.3 OCH.sub.3 H H H H H H H H 2 ##STR55## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR56## H OC.sub.2 H.sub.5 H H H H H H H H H 1 ##STR57## H OCH.sub.3 OCH.sub.3 OCH.sub.3 H H H H H H H 1 ##STR58## OCH.sub.3 OH H H H H H H H H H 1 ##STR59## H OCH.sub.3 Br H H H H H H H H 1 ##STR60## H OCH.sub.3 Cl Cl H H H H H H H 1 ##STR61## H OCH.sub.3 CF.sub.3 H H H H H H H H 2 ##STR62## H ##STR63## H H H H H H H H 3 ##STR64## H OCH.sub.3 H H CH.sub.3 H H H H H H ##STR65## H OCH.sub.3 H OCH.sub.3 CH.sub.3 H CH.sub.3 H H H H 3 ##STR66## H OCH.sub.3 OCH.sub.3 OCH.sub.3 H H H CH.sub.3 H H H 4 ##STR67## H H H OCH.sub.3 H H H ##STR68## H H H 4 ##STR69## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H H 2 ##STR70## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 H 2 ##STR71## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR72## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H H 2 ##STR73## H ##STR74## H H H H H CH.sub.3 CH.sub.3 H 2 ##STR75## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR76## H OCH.sub. 3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H H 2 ##STR77## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 H 2 ##STR78## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR79## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR80## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 H 2 ##STR81## H OCH.sub. 3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR82## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 2 ##STR83## H OCH.sub.3 OCH.sub.3 H H H H H H H CH.sub.3 2 ##STR84## H OCH.sub.3 OCH.sub.3 H H H H H H CH.sub.3 2 ##STR85## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H CH.sub.3 2 ##STR86## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 2 ##STR87## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 CH.sub.3 2 ##STR88## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H CH.sub.3 2 ##STR89## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 2 ##STR90## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 CH.sub.3 2 ##STR91## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 3 ##STR92## H OCH.sub.3 OCH.sub.3 H H H H H H HCH.sub.3 4 ##STR93## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H CH.sub.3 2 ##STR94## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 2 ##STR95## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 CH.sub.3 2 ##STR96## H ##STR97## H CH.sub.3 CH.sub.3 H H H H ##STR98## 2 ##STR99## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H ##STR100## 2 ##STR101## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 ##STR102## 2 ##STR103## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H ##STR104## 2 ##STR105## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H ##STR106## 2 ##STR107## H OCH.sub.3 OCH.sub.3 H H H Cl H CH.sub.3 CH.sub.3 ##STR108## 2 ##STR109## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H ##STR110## 2 ##STR111## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H ##STR112## 2 ##STR113## H OCH.sub.3 OCH.sub.3 H H H H H CH.sub.3 CH.sub.3 ##STR114## 2 ##STR115## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H ##STR116## 2 ##STR117## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H ##STR118## 2 ##STR119## H OCH.sub.3 OCH.sub.3 H H H C.sub.3 H.sub.7 H CH.sub.3 CH.sub.3 ##STR120## ##STR121## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H CH.sub.3 3 ##STR122## H H H OCH.sub.3 C.sub.2 H.sub.5 C.sub.2 H.sub.5 H H H H H 3 ##STR123## H OCH.sub.3 OCH.sub.3 H C.sub.3 H.sub.7 C.sub.3 H.sub.7 H H H H H 3 ##STR124## H OC.sub.2 H.sub.5 H H CH.sub.3 CH.sub.3 H H H H CH.sub.3 3 ##STR125## H OCH.sub.3 OCH.sub.3 H nC.sub.4 H.sub. 9 nC.sub.4 H.sub.9 H H H H H 2 ##STR126## OH H H H C.sub.2 H.sub.5 C.sub.3 H.sub.7 H H H H H 3 ##STR127## H OCH.sub.3 OCH.sub.3 H H H H H H H H 2 ##STR128## H OCH.sub.3 OCH.sub.3 H Cl H H H H H H 1 ##STR129## H OCH.sub.3 CF.sub.3 H H H H H H H CH.sub.3 3 ##STR130## H ##STR131## H ##STR132## H H H H H H 1 ##STR133## H OCH.sub.3 OCH.sub.3H CH.sub.3 H H H H H H 1 ##STR134## H OCH.sub.3 H H ##STR135## H H H H H CH.sub.3 2 ##STR136## H OCH.sub.3 H H OCH.sub.3 H H H H H H 2 ##STR137## H OCH.sub.3 OCH.sub.3 H Br H H CH.sub.3 CH.sub.3 H H 2 ##STR138## H OC.sub.2 H.sub.5 H H Cl H CH.sub.3 H H H H 2 ##STR139## H OCH.sub.3 OCH.sub.3 OCH.sub.3 H CH.sub.3 ##STR140## H H H 2 ##STR141## H OCH.sub.3 H H CH.sub.3 Cl H H H H H 3 ##STR142## H OCH.sub.3 H H Cl H H H H H H 3 ##STR143## H OCH.sub.3 Cl H H H H H H H CH.sub.3 2 ##STR144## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H H 2 ##STR145## H H OCH.sub.3 H CH.sub.3 H CH.sub.3 H H H CH.sub.3 5 ##STR146## H CH.sub.3 H H OCH.sub.3 H H H H H CH.sub.3 5 ##STR147## H H H OCH.sub.3 H H H ##STR148## H H CH.sub.3 3 ##STR149## H OCH.sub.3 H H H H H H H H H 3 ##STR150## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub. 3 H H H H H 4 ##STR151## ##STR152##

Following the procedure used in Example 1 through 11, but substituting hal branched chain benzoxepins for the corresponding 1-haloalkylbenzoxepins the following compounds can be made. ##STR153## R.sub.1 ' R.sub.1 " R.sub.1 "' R.sub.1 "" R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6 R.sub.7 R.sub.8 Branched Chain NR.sub.9 R.sub.10 H H C.sub.3 H.sub.7 OCH.sub.3 H H H H H H H ##STR154## ##STR155## H H H OCH.sub.3 H H H H H H H ##STR156## ##STR157## OCH.sub.3 OCH.sub.3 H H H H H H H H H ##STR158## ##STR159## H OC.sub.2 H.sub.5 H H H H H H H H H ##STR160## ##STR161## H OCH.sub.3 OCH.sub.3 OCH.sub.3 H H H H H H H ##STR162## ##STR163## H OH OCH.sub.3 H H H H H H H H ##STR164## ##STR165## H OCH.sub.3 Br H H H CH.sub.3 H H H H ##STR166## ##STR167## H OCH.sub.3Cl Cl H H H H H H H ##STR168## ##STR169## H OCH.sub.3 CF.sub.3 H H H H H H H H ##STR170## ##STR171## H ##STR172## H H H H H H H H ##STR173## ##STR174## H OCH.sub.3 H H CH.sub.3 H H H H H H ##STR175## ##STR176## H OCH.sub.3 H OCH.sub.3 CH.sub.3 H CH.sub.3 H H H H ##STR177## ##STR178## H OCH.sub.3 OCH.sub.3 OCH.sub.3 H H H CH.sub.3 H H H ##STR179## ##STR180## H H H OCH.sub.3 H H H ##STR181## H H H ##STR182## ##STR183## H OH H H H Br H H H H H ##STR184## ##STR185## H OCH.sub.3 OCH.sub.3 H CH.sub.3 CH.sub.3 H H H H CH.sub.3 ##STR186## ##STR187## H OCH.sub.3 OCH.sub.3 H H H CH.sub.3 CH.sub.3 H H CH.sub.3 ##STR188## ##STR189## H OCH.sub.3 OCH.sub.3 H H H ##STR190## H H CH.sub.3 ##STR191## ##STR192## H OC.sub.3 H.sub.7 OC.sub.3 H.sub.7 H H H H H H H ##STR193## ##STR194## ##STR195##

A mixture of 0.50 g (1.07 mmoles) of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl)methoxy]ethyl]-4-ni trobenzenesulfonate, 0.22 g (1.07 mmoles) of o-methoxyphenylpiperazine, 0.15 ml (1.07 mmoles) of triethylamine, and 20 ml of tetrahydrofuran is stirred at room temperature for 24 hours. After removing the tetrahydrofuran in vacuo, the reaction mixture is extracted with methylene chloride and aqueous sodium bicarbonate. The organic layer is filtered through sodium sulfate, taken to drynes, and chromatographed on silica gel using 3% methanol:methylene chloride eluent to give 0.40 g (82%) of 1-[2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl)methoxy]ethyl]-4 -(2-methoxyphenyl)piperazine. The dihydrochloride salt was prepared with hydrochloric acid in ethyl ether, m.p. 172.degree.-175.degree..

Analysis: Calc'd. for C.sub.26 H.sub.36 N.sub.2 O.sub.5 .multidot.2HCl.multidot.H.sub.2 O C, 57.03; H, 7.36; N, 5.12; Cl, 12.95. Found: C, 56.94; H, 7.29; N, 5.48; Cl, 12.98.

A mixture of 0.10 g (1.50 mmoles) of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepine-1-yl)methoxy]ethyl 4-nitrobenzenesulfonate, 0.37 g (1.50 mmoles) of 4-hydroxy-4-(3-trifluoromethylphenyl)piperidine, 0.21 ml (1.50 mmoles) of triethylamine and 30 ml of tetrahydrofuran is stirred at room temperature for 3 days, at 50.degree. for 1 day, and again at room temperature for 2 days, after which the tetrahydrofuran is removed in vacuo.

The reaction mixture is extracted with methylene chloride and aqueous sodium bicarbonate. The organic layer is filtered through sodium sulfate and taken to dryness and chromatographed on silica gel with 2% methanol:05% ammonium hydroxide:methylene chloride as eluent to give 0.46 g (60%) of the titled product. The hydrochloride salt is prepared with hydrochloric acid/ethyl ether, m.p. 156.degree.-159.degree..

Analysis:

Calc'd. for C.sub.27 H.sub.34 F.sub.3 NO.sub.5 .multidot.HCl.multidot..sub.2 H.sub.2 O

C, 58.43; H, 6.54; N, 2.52; Cl, 6.34.

Found: C, 58.60; H, 6.49; N, 2.85; Cl, 7.08.

A mixture of 400 mg of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl)methoxy]ethyl-4-nit robenzenesulfonate, 150 mg of 4-fluorophenylpiperazine, 0.12 ml of triethylamine and tetrahydrofuran as solvent is stirred at room temperature for 18 hours after which the tetrahydrofuran is removed in vacuo. The reaction mixture is extracted with methylene chloride and aqueous sodium bicarbonate. The organic layer is filtered through sodium sulfate and taken to dryness. The residue is purified by chromatography. The product is crystallized from methylene chloride and Skelly B, and ether, m.p. 114.degree.-114.5.degree..

A mixture of 1.27 g (4.42 mmoles) of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1-yl)methoxy]ethyl chloride, and 1.52 g (8.44 mmoles) of 1-fluorophenyl piperazine is stirred for 60 hours at 90.degree., neat. The product is isolated and crystallized as in Example 15.

A mixture of 1.00 g (3.32 mmoles) of 2-[(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepin-1yl)methoxy]ethyl chloride and 1.14 g (6.65 mmoles) of 95% 2-pyridylpiperazine is stirred at 90.degree. for 20 hours. Approximately 3 ml of toluene is then added and the reaction mixture is heated for an additional 28 hours. After cooling, the reaction mixture is filtered, washing with toluene, and the filtrate is extracted with (1) aqueous sodium bicarbonate and (2) brine. The organic layer is taken to dryness and the residue is chromatographed on silica gel using 3% methanol:0.5% ammonium hydroxide in methylene chloride as eluent to give 1.30 g (92%) of the stated product. The hydrochloric acid salt (dihydrate) was prepared from hydrogen chloride in ethanol.

Analysis: Calc'd. for C;hd 24H.sub.33 N.sub.3 O.sub.4 .multidot.HCl.multidot.2H.sub.2 O C, 57.65; H, 7.46; N, 8.40. Found: C, 57.31; H, 7.69; N, 8.23.

Following the procedure used in Example 12 through 17 but substituting the appropriate 1-[2-[(1,3,4,5-tetrahydro-2-benzoxepin-1-yl)alkoxy]alkyl]chlorines or benzene sulfonates and the appropriate amines, the following compounds can be made.

Following procedure similar to those of Examples 1 to 11, but substituting the appropriate 1-haloalkyl-2-benzothiepin for 1-haloalkyl-2-benzoxepin, benzothiepins of Table 11 can be prepared.

Following procedures similar to those Examples 1-10 and 12 and substituting the appropriate 1-haloalkyl-2-benzothiepin for 1-haloalkyl-2-benzoxepin, 2-benzothiepins with brached-chain amines (Table 12) can be prepared.

Following procedures similar to those of Examples 13 through 18, but substituting the appropriate (1,3,4,5-tetrahydro-2-benzothiepin-1-yl)alkoxy alkyl halides or benzenesulfonates for the corresponding benzoxepins, the benzothiepins of Table 13 can be prepared.

A mixture of 1.52 g of 6,7-dimethoxy-4,4-dimethyl-1-bromoethylisochroman, 1.35 g of 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine, and 2 ml. of triethylamine in 5 ml of DMF are heated at 50.degree. C. for 23 hr. The mixture is partitioned between methylene chloride and aqueous potassium carbonate. The organic phase is dried over sodium sulfate and concentrated. The residue is chromatographed over silica gel utilizing 5% methanol/1/2%ammonium hydroxide/methylene chloride to give a 21% yield 4-(4-chloro phenyl)-1-[(3,4-dihydro-4,4-dimethyl-6,7-dimethoxy-1H-2-benzopyran-1-yl)me thyl]-1,2,3,6-tetrahydropyridine.

The salt is prepared from hydrogen chloride in ether and recrystallized from ethanol/ethyl acetate, mp 250.degree.-252.degree..

Anal. Calcd for C.sub.25 H.sub.30 NO.sub.3 Cl.HCl Calcd: C, 64.65; H, 6.73; N, 3.01; Cl, 15.27 Found: C, 63.16; H, 6.78; N, 2.98; Cl, 14.87.

A solution of 1-methyl-1-(3-chloropropyl)-3,4-dihydro-6,7-dimethoxy-1H-2-benzopyran (0.6 g., 0.002 mole), p-fluoropiperazine (0.4 g., 0.002 mole) and 0.5 g. of triethylamine in 10 ml. of ethylene glycol is heated to 80.degree. C. under nitrogen for twenty hours. The reaction mixture is poured into water and extracted with methylene chloride. The methylene chloride solution is washed with water, a saturated solution of sodium chloride, dried over sodium sulfate and concentrated to an oil. The oil is chromatographed on a silica gel column using 5% methanol/methyl chloride as eluent to yield 500 mg. of 1-methyl-1-[3-(3,4-dihydro-6,7-dimethoxy-1H-2-benzopyran-1-yl)propyl]-4-(4 -fluorophenyl)piperazine as a white oil. This is reacted with ethereal HCl and the product recrystallized from methanol/ether to yield 300 mg. of 1-methyl-1-[3-(3,4-dihydro-6,7-dimethoxy-1H-2-benzopuran-1-yl)propyl]-4-(4 -fluorophenyl)piperazine, dihydrochloride, m.p. 240.degree.-242.degree. C.

A mixture of 1.50 g. (0.0053 m) of 2-(6,7-dimethoxy-4,4-dimethyisochroman-1-yl)ethyl chloride, 2.48 g. (0.011 m) of 3-trifluoromethylphenylpiperazine and 30 ml of ethylene glycol is stirred at 55.degree. for 24 hr. The mixture is partitioned between methylene chloride and sodium bicarbonate. The organic base is concentrated and chromatographed. The salt of the title compound is prepared from ethereal hydrogen chloride. The yield is 0.83 g., mp 162.degree.-163.5.degree. C.

Anal. Calcd. for C.sub.26 H.sub.23 N.sub.2 F.sub.3 O.sub.3.2HCl Calcd: C, 56.62; H, 6.39; N5.08; Cl, 12.86; Found: C, 56.52; H, 6.52; N, 5.02; Cl, 11.25.

A mixture of 2.0 g of [2-(6,7-dimethoxy-4,4-dimethylisochroman-1-yl)ethyl]-[2-(3,4-dimethoxyphen yl)ethyl]-amine, 500 mg of paraformaldehyde, 25 ml of toluene, and 10 ml of nitrobenzene is heated at 100.degree. for 4 hours. The mixture is partitioned between methylene chloride and water. The organic phase is concentrated and chromatographed to yield the title compound which is converted to its hydrogen chloride salt and crystallized from ethyl acetate to give 800 mg of the title compound as its salt, mp 100.degree.-105.degree..

Anal. Calcd. for C.sub.26 H.sub.35 NO.sub.5 .multidot.HCl.multidot.11/2H.sub.2 O Calcd: C, 61.82; H, 7.38; N, 2.77; Cl, 7.03; Found: C, 61.26; H, 7.30; N, 2.90; Cl, 7.03

In the manner of examples 20,21a, and 21b, the following isochromans are prepared from the appropriate (6,7-dimethoxyisochroman-1-yl)alkyl halides and the appropriate amines. (Table 14).

Following procedures similar to those of Examples 20-21C, but substituting the appropriate (isochroman-1-yl)alkyl halides and the appropriate amines, the following compounds can be made.

Following procedures similar to those in Examples 20-22, but substituting the appropriate [isochroman-1-yl]-alkyl halides and the appropriate amines, the following compounds are made.

Following the procedures described in Preparation 8, and in Examples 13 through 18, but substituting either the appropriate isochroman-1-yl alcohols or [isochroman-1-yl]-alkoxyalkyl chlorides, or [isochroman-1-yl]alkoxyalkyl benzenesulfonates, the following compounds are made (Table 17).

A mixture of 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine and (3,4-dihydro-4,4-dimethyl-6,7-dimethoxy-1H-2-benzothiopyran-1-yl)methyl chloride are heated in toluene. The mixture is partitioned between methyline chloride and sodium carbonate. The product stated above is isolated from the organic phase by chromatography and crystallization.

Following the procedures similar to those used in Examples 20-22 and 25, but substituting the appropriate (lsothiochroman-1-yl)alkyl halide for (isochroman-1-yl)-alkyl halide and the appropriate amines, the following compounds can be prepared (Table 18).

Following the procedures similar to those used in Examples 22-23 and 25, but substituting the appropriate (isothiochroman-1-yl)alkyl halides for (isochroman-1-yl)-alkyl halides, and the appropriate amines, the following compounds can be made (Table 19).

A mixture of `-[[1-methyl-6,7-dimethoxy-3,4-dihydro-1H-2-benzothiopyran-1-yl]methoxy]et hanol-4-nitrobenzenesulfonate and piperidine is stirred at from temperature in THF. The mixture is then partitioned between methylene chloride and aqueous sodium carbonate. The title compound is isolated by chromatography and is crystallized.

The compounds of Table 20 can be prepared using the procedures of Examples 13-18, 19, and 24 starting from the appropriate [3,4-dihydro-1H-2-benzothioyran-1-yl]-alkoxy alkanols or their benzenesulfonates, or the corresponding chlorides and the appropriate amines.

A lot of 10,000 tablets, each containing 25 mg of 1-[2-(6,7-dimethoxy-4,4-dimethylisochroman-1-yl)ethyl]-4-(2-methyl)piperaz ine is prepared from the following types and amounts of ingredients:

The compound and dicalcium phoshate are mixed well, granulated with 7.5 percent solution of methyl cellulose in water, passed through a No. 8 screen and dried carefully. The dried granules are passed through a No. 12 screen, mixed thoroughly with the talc, starch and magnesium stearate, and compressed into tablets.

These tablets are useful in treating hypertension at a dose of two tablets per day.

A lot of 10,00 tablets, each containing 50 mg of N-[(7,8-dimethoxy-2-benzoxepin-1-yl)methyl]-(6,7-dimethoxy-1,2,3,4-tetrahy droquinoline) is prepared from the following types and amounts of ingredients

The compound an dicalcium phoshate are mixed well, granulated with 7.5 percent solution of methyl cellulose in water, passed through a No. 8 screen and dried carefully. The dried granules are passed through a No. 12 screen, mixed thoroughly with the talc, starch and magnesium stearate, and compresed into tablets.

These tablets are useful in treating CNS disorders, particularly psychosis, at a dose of one tablet every eight hours.

A sterile preparation suitable for intramuscular injection and containing 25 mg of 1-[2-(6,7-dimethoxy-4,4-dimethylisochroman-1-yl)ethyl]-4-(2-methylphenyl)p iperazine hydrochloride in each milliliter is prepared from the following types and amounts of ingredients:

One milliliter of this sterile preparation is injected for treatment of hypertension two times a day.

A sterile preparation suitable for intramuscular injection and containing 60 mg of N-[(7,8-dimethoxy-2-benzoxepin-1-yl)methyl]-(6,7-dimethoxy-1,2,3,4-tetrahy droquino line) hydrochloride in each milliliter is prepared from the following ingredients:

One milliliter of this sterile preparation is injected for the treatment of psychosis at intervals of 8 hours.

One thousand two-piece hard gelatin capsules for oral use, each containing 30 mg of 1-[(2-(6,7-dimethoxy-4,4-dimethylisochroman-1-yl)ethyl]-4-(2-methylphenyl) piperazine are prepared from the following ingredients:

The micronized active ingredient is mixed with the starch-lactose mixture followed by the talc and calcium stearate. The final mixture is then encapsulated in the usual manner.

One capsule every 12 hours is administered to treat hypertension.

One thousand two-piece hard gelatin capsules for oral use, each containing 60 mg of N-[7,8-dimethoxy-2-benzoxepin-1-yl)methyl]-(6,7-dimethoxy-1,2,3,4-tetrahyd roisoquinoline) are prepared from the following ingredients:

The micronized active ingredient is mixed with the starch-lactose mixture followed by the talc and calcium stearate. The final mixture is then encapsulated in the usual manner. One capsule is used every 8 hours to treat CNS disorders, particularly psychosis.

An aqueous preparation for oral use containing in each 5 ml (1-teaspoon) 50 mg of 1-[2-(6,7-dimethoxy-4,4-dimethylisochroman-1-yl)ethyl-]4-(2-methylphenyl)p iperazine is prepared from the following ingredients:

A dose of one teaspoon per day is useful for treating hypertension.

An aqueous preparation for oral use containing in each teaspoon (5ml) 75 mg of N-[(7,8-dimethoxy-2-benzoxepin-1-yl)methyl]-(6,7-dimethoxy-1,2,3,4-tetrahy droisoquinoline) for use in treating psychotic disorders is prepared from the following ingredients:

A dose of one to two teaspoons per day is useful in treating CNS diseases, particularly psychosis.